Predictive Oncology Q3 revenue $455.8K (+45% YoY); appoints new CEO Raymond Vennare

Axe Compute Inc.

2022-Q3 EPS reported -$0.25 revenue$1,141,986

Q3 revenue $455,827, up 45% from $313,663 in Q3 2021; gross margin improved to 76% from 65%.
Net loss for nine months $17.8M vs $11.9M year ago, including $7.2M goodwill impairment for zPREDICTA.
Raymond F. Vennare appointed CEO and Chairman; he has 30+ years biotech experience.
R&D expenses down 50% to $116,763; G&A up to $3.29M due to acquisition and CEO retirement costs.
Cash and equivalents $25.4M at Sept 30, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axe Compute Inc. reported third quarter ended September 30, 2022 results: revenue $455,827.

Period: third quarter ended September 30, 2022
Revenue: $455,827
Result: reported results

Exact text from the filing

issues surrounding the therapeutic use of human tissue and cells. Q3 2022 Financial results The consolidated reportable segments of Predictive Oncology’s recognized revenue is $455,827 for the quarter, which has increased from $313,663 to the comparative three-month period of 2021, which depicts a revenue growth of 45%. Helomics reported an improvement in its

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007386

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.